<- Go Home
Vor Biopharma Inc.
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Market Cap
$56.1M
Volume
404.3K
Cash and Equivalents
$52.8M
EBITDA
-$114.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.14
52 Week Low
$0.63
Dividend
N/A
Price / Book Value
0.77
Price / Earnings
-0.50
Price / Tangible Book Value
0.77
Enterprise Value
$26.1M
Enterprise Value / EBITDA
-0.25
Operating Income
-$118.0M
Return on Equity
-90.79%
Return on Assets
-43.51
Cash and Short Term Investments
$62.8M
Debt
$32.9M
Equity
$73.0M
Revenue
N/A
Unlevered FCF
-$62.0M
Sector
Biotechnology
Category
N/A
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick Premium